Cervical cancer, human papillomavirus (HPV) infection Cancer Cervical cancer, human papillomavirus (HPV) infection
Conditions
Interventions
All women were screened by both self-sampling (using XytoTest) and clinician collected cytology (using ThinPrep). Both samples were HPV tested with HPV DNA (Abbott) and HPV mRNA (Proofer 7). All women
Sponsors
Hospital General de México
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Sexually active women 2. Aged between 30 and 65 years 3. Responded positively to the invitation
Exclusion criteria
Exclusion criteria: 1. Pregnant or breastfeeding 2. Sexual activity =24 h before the collection of samples 3. History of medical or surgical treatment (radiotherapy, chemotherapy, hysterectomy, or cone biopsy) for cervical cancer
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. HPV test result for samples collected from the same patient using both the XytoTest and ThinPrep sampling devices measured using an HPV DNA test (Abbott RealTime HR HPV test) and an HPV mRNA test (PreTect HPV-Proofer 7) at a single timepoint | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Patient-reported acceptability of the self-collected samples method measured using a four-question questionnaire directly after self-testing using the XytoTest device | — |
Countries
Mexico
Outcome results
None listed